Anthem Biosciences Gains 12.28%: 6 Key Factors Driving the Week’s Momentum

6 April 2026: Downgrade to Sell Amid Technical and Financial Weakness

MarketsMOJO downgraded Anthem Biosciences Ltd from Hold to Sell on 6 April 2026, citing deteriorating technical indicators and disappointing quarterly financial results. The Mojo Score fell to 40.0, reflecting concerns over valuation, financial trends, and quality metrics. The stock closed at ₹663.35, showing no immediate reaction to the downgrade but setting a cautious tone for the week ahead.

The downgrade was driven by a shift from mildly bullish to sideways technical momentum, with key indicators such as weekly and monthly RSI and Bollinger Bands signalling a lack of clear directional movement. Financially, the company reported a 14.1% decline in net profit after tax for Q3 FY25-26, alongside reduced net sales and PBDIT, raising concerns about near-term earnings sustainability despite a strong longer-term growth trajectory.

7 April 2026: Sideways Technical Momentum Amid Mixed Market Signals

On 7 April, Anthem Biosciences closed slightly lower at ₹658.90, down 0.35% from the previous day. Technical momentum shifted to a sideways trend, with the weekly MACD remaining mildly bullish but monthly indicators neutral. The stock traded within a narrow range, reflecting consolidation after the downgrade.

Volume remained subdued, and moving averages failed to provide clear directional cues. Despite this, the stock’s year-to-date performance of +1.21% outpaced the Sensex’s 13.04% decline, highlighting relative resilience amid sector weakness. The sideways trend suggested a pause in momentum, with investors awaiting clearer signals.

8 April 2026: Mildly Bullish Momentum Emerges with Technical Upgrades

The stock rebounded strongly on 8 April, closing at ₹689.85, up 3.39%. Technical indicators improved as the weekly MACD turned mildly bullish and Bollinger Bands expanded, signalling increased volatility and upward pressure. Despite the Mojo Grade remaining at Sell, the technical upgrades suggested a potential shift towards positive momentum.

However, daily moving averages and RSI remained inconclusive, and volume-based indicators like On-Balance Volume (OBV) showed no confirming trend. The stock’s price remained well below its 52-week high of ₹873.25 but comfortably above its low of ₹579.45, indicating a recovery phase within a broader trading range.

9 April 2026: Intraday High and Mixed Technical Signals

On 9 April, Anthem Biosciences surged 5.83% intraday to a high of ₹728.5, closing at ₹720.50, marking the fourth consecutive day of gains and a total return of 10.18% over this period. The stock outperformed both its sector peers and the Sensex, which declined 0.49% that day.

Technically, the stock traded above all key moving averages, reinforcing a strong upward trend. Weekly MACD and Bollinger Bands were bullish, while Dow Theory assessments indicated mild bullishness. However, weekly OBV remained bearish, reflecting some divergence between price and volume trends. The mixed signals suggested cautious optimism amid strong price action.

9 April 2026: Technical Momentum Shift Amid Mixed Market Signals

Later on 9 April, technical momentum was reassessed as shifting from mildly bullish to mildly bearish despite the positive price movement. The weekly MACD remained mildly bullish, but monthly indicators and OBV showed bearish or neutral signals. RSI readings were neutral, and Bollinger Bands remained bullish on the weekly chart, highlighting a nuanced technical landscape.

The stock’s relative outperformance over one month (+4.36%) and year-to-date (+5.96%) contrasted with the Sensex’s declines, but the one-week gain of 3.42% lagged the Sensex’s 6.06% advance. This divergence underscored the complexity of the stock’s momentum amid sector volatility and mid-cap sensitivities.

10 April 2026: Technical Momentum Shifts to Mildly Bullish with Strong Price Gains

On the final trading day of the week, Anthem Biosciences closed at ₹744.80, up 3.37% from the previous close, marking a 12.28% gain for the week. The stock demonstrated renewed technical momentum, shifting from mildly bearish to mildly bullish, supported by a strongly positive weekly MACD and bullish Bollinger Bands.

Dow Theory assessments on both weekly and monthly charts confirmed a mildly bullish trend, although volume indicators such as weekly OBV remained bearish, suggesting the rally may lack broad market participation. The RSI remained neutral, indicating the stock was neither overbought nor oversold.

Despite the recent downgrade to Sell and a Mojo Score of 40.0, Anthem Biosciences outperformed the Sensex significantly, which gained 1.40% on the day and 5.34% over the week. The stock’s current price remains approximately 17% below its 52-week high, leaving room for potential further gains if momentum sustains.

Key Takeaways

The week for Anthem Biosciences Ltd was characterised by a strong price rally of 12.28%, more than doubling the Sensex’s 5.34% gain. This outperformance was driven by a series of technical momentum shifts, from sideways consolidation to mildly bullish trends, supported by key indicators such as the weekly MACD and Bollinger Bands.

However, the stock’s technical landscape remains mixed, with bearish volume trends and neutral RSI readings tempering enthusiasm. The recent downgrade to a Sell rating by MarketsMOJO reflects concerns over financial performance and valuation, despite the stock’s resilience and relative strength within the Pharmaceuticals & Biotechnology sector.

Investors should note the stock’s recovery from a low near ₹663 to a high of ₹744.80 within five trading days, signalling strong short-term momentum. Yet, the absence of volume confirmation and the cautious analyst stance suggest that volatility and technical uncertainty may persist.

Overall, Anthem Biosciences presents a nuanced picture: a mid-cap stock showing robust price gains amid mixed technical and fundamental signals, warranting close monitoring for confirmation of sustained trends.

Conclusion

Anthem Biosciences Ltd’s week from 6 to 10 April 2026 was marked by significant price appreciation and evolving technical momentum. Despite a downgrade to Sell and mixed indicator signals, the stock outperformed the broader market and demonstrated resilience amid sector challenges.

The interplay of bullish weekly MACD and Bollinger Bands with bearish volume trends and neutral RSI highlights the complexity of the current market environment. Investors should approach the stock with a balanced perspective, considering both the strong short-term gains and the cautionary signals embedded in its technical and fundamental profile.

As Anthem Biosciences navigates this transitional phase, further price action and volume confirmation will be critical to validate the emerging bullish momentum or signal a potential reversal. The stock’s mid-cap status and sector dynamics add layers of risk and opportunity that merit careful analysis in the coming weeks.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →